Caution, This content is for veterinary professionals.

Virbagen® Omega

Parvovirus need not be a death sentence

Virbagen® Omega contains recombinant interferon omega of feline origin. Type I interferons are cytokines that act as protein messengers which induce multiple immune pathways in the cell. These include the increased production of potent anti-viral proteins and enzymes. Licensed to treat Canine Parvovirus, Virbagen® Omega is administered intravenously and is proven to decrease mortality rate when used in conjunction with supportive therapies.

Product Features & Benefits: 

  • Licensed for the treatment of parvovirus in dogs

  • Mortality in dogs is reduced by 4.4x when using Virbagen® Omega in combination with supportive therapy rather than supportive therapy alone.1

  • When looking specifically at an unvaccinated population, the use of Virbagen® Omega decreases mortality by 6.4 times

  • Reduces clinical signs of parvovirus to facilitate a quicker recovery1

  • The canine dose 2.5 MU/Kg IV once daily for 3 days.Use in a 10kg dog would require 25MU per day and therefore 75MU for the course.  One vial of reconstituted Virbagen® Omega contains 10MU of interferon,which would result in 2.5 vials per day for this example

  • Licensed, also, to treat FeLV and FIV/FeLV co-infected cats where it is proven to:

    • Significantly reduce the clinical signs 

    • Decrease overall mortality rate 

    • Improve overall quality of life 

  • In cats, Virbagen® Omega should be injected subcutaneously once daily for five consecutive days, at a dose rate of 1 MU/kg bodyweight, starting on days 0, 14 and 60.


Presentations Available: 

Available in 2 and 5 vial packs.


Available UK & Ireland logo.jpg

Use medicines responsibly.
Further information is available on the SPC or on request from Virbac Ltd.


1. K. De Mari et al. Treatment of canine parvovirus enteritis with interferon-omega in a placebo-controlled field trial, Veterinary Record (2003) 152, 105-108.